This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. AMRN, ANNX, ALMS, GOSS, IVA, FULC, ELDN, NGNE, ESPR, and YMABShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Amarin (AMRN), Annexon (ANNX), Alumis (ALMS), Gossamer Bio (GOSS), Inventiva (IVA), Fulcrum Therapeutics (FULC), Eledon Pharmaceuticals (ELDN), Neurogene (NGNE), Esperion Therapeutics (ESPR), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Amarin Annexon Alumis Gossamer Bio Inventiva Fulcrum Therapeutics Eledon Pharmaceuticals Neurogene Esperion Therapeutics Y-mAbs Therapeutics Amarin (NASDAQ:AMRN) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Do institutionals & insiders believe in AMRN or ELTX? 22.3% of Amarin shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 2.0% of Amarin shares are held by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to AMRN or ELTX? In the previous week, Amarin had 10 more articles in the media than Elicio Therapeutics. MarketBeat recorded 10 mentions for Amarin and 0 mentions for Elicio Therapeutics. Amarin's average media sentiment score of 0.62 beat Elicio Therapeutics' score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Overall Sentiment Amarin Positive Elicio Therapeutics Neutral Which has better earnings and valuation, AMRN or ELTX? Elicio Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M0.98-$59.11M-$4.00-2.73Elicio Therapeutics$2.30M25.80-$35.19M-$6.95-0.79 Do analysts rate AMRN or ELTX? Amarin currently has a consensus price target of $7.00, suggesting a potential downside of 35.84%. Elicio Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 81.82%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AMRN or ELTX more profitable? Elicio Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Elicio Therapeutics N/A -555.45%-177.34% Which has more volatility & risk, AMRN or ELTX? Amarin has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Does the MarketBeat Community favor AMRN or ELTX? Amarin received 837 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Elicio Therapeutics an outperform vote while only 73.26% of users gave Amarin an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84473.26% Underperform Votes30826.74% Elicio TherapeuticsOutperform Votes787.50% Underperform Votes112.50% SummaryElicio Therapeutics beats Amarin on 9 of the 17 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.35M$6.86B$5.57B$8.05BDividend YieldN/A2.89%5.36%4.23%P/E Ratio-0.797.5422.8118.90Price / Sales25.80259.70406.31107.03Price / CashN/A65.8538.1834.62Price / Book4.076.566.794.34Net Income-$35.19M$143.88M$3.23B$248.27M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics2.6855 of 5 stars$5.50+9.6%$10.00+81.8%-38.8%$59.35M$2.30M-0.79N/AGap UpAMRNAmarin0.5546 of 5 stars$10.33+0.1%$7.00-32.2%-40.1%$212.12M$228.61M-114.78360Upcoming EarningsANNXAnnexon1.3526 of 5 stars$1.90+0.5%$18.67+882.5%-59.6%$208.46MN/A-1.8160Upcoming EarningsPositive NewsALMSAlumis2.1656 of 5 stars$4.33+5.1%$25.86+497.2%N/A$204.47MN/A0.00N/AAnalyst ForecastNews CoverageGOSSGossamer Bio3.9286 of 5 stars$0.88+0.6%$7.50+750.6%+59.5%$200.34M$114.70M-2.76180Upcoming EarningsNews CoverageIVAInventiva1.7086 of 5 stars$3.81+0.1%$10.40+173.3%+2.4%$199.68M$9.20M0.00100FULCFulcrum Therapeutics1.7375 of 5 stars$3.65+2.2%$8.63+136.3%-27.5%$197.02M$80M-11.77100Earnings ReportNews CoverageELDNEledon Pharmaceuticals2.2131 of 5 stars$3.27-0.3%$12.50+282.3%+37.3%$195.81MN/A-1.6310Upcoming EarningsShort Interest ↑News CoverageNGNENeurogene1.9658 of 5 stars$13.03-10.1%$47.20+262.2%-53.7%$194.54M$925,000.00-3.0590Upcoming EarningsNews CoverageESPREsperion Therapeutics3.4498 of 5 stars$0.96+5.8%$6.42+568.5%-47.6%$190.20M$332.31M-1.50200Upcoming EarningsAnalyst RevisionNews CoverageGap UpYMABY-mAbs Therapeutics3.8454 of 5 stars$4.20-0.7%$17.40+314.3%-74.3%$189.92M$87.69M-7.78150Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies AMRN Competitors ANNX Competitors ALMS Competitors GOSS Competitors IVA Competitors FULC Competitors ELDN Competitors NGNE Competitors ESPR Competitors YMAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELTX Stock Free ELTX Stock Alerts